Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
4D Pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate
-
Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit
-
Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit
-
LifeSci Acquisition Corp. Announces Closing of $60 Million Initial Public Offering
-
Axial Biotherapeutics to Present at the Chardan 2nd Annual Microbiome Medicines Virtual Summit
-
Krystal Biotech (KRYS) PT Raised to $100 at Chardan Capital Markets
-
Kaleido Biosciences to Present During Chardan’s 2nd Annual Microbiome Medicines Summit
-
Kaleido Biosciences to Present During Chardan’s 2nd Annual Microbiome Medicines Summit
-
Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares
-
Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares
-
Form S-1 Chardan Healthcare Acqui
-
Chardan Capital Markets Starts NeuBase Therapeutics (NBSE) at Buy
-
LifeSci Acquisition Corp (LSAC) Prices 6M Unit IPO at $10/Unit
-
Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy Ahead of HBV Clinical Data
-
LifeSci Acquisition Corp. Announces Pricing of $60 Million Initial Public Offering
-
uniQure BV (QURE) PT Lowered to $105 at Chardan Capital Markets
-
uniQure to Participate in Multiple Upcoming Industry Conferences in March
-
uniQure Announces 2019 Financial Results and Highlights Recent Company Progress
-
Form X-17A-5 CHARDAN CAPITAL MARKETS For: Dec 31
-
Passage Bio (PASG) IPO Opens 24% Higher
-
Passage Bio, Inc. (PASG) Prices 12M Share IPO at $18/Sh
-
Passage Bio Announces Pricing of Initial Public Offering
-
Passage Bio Announces Pricing of Initial Public Offering
-
Update: EdtechX Holdings (NASDAQ: EDTX) : Trading Update From Meten International Education Group
-
EdtechX Holdings (NASDAQ: EDTX) : Trading Update From Meten International Education Group
-
Trading Update Meten International Education Group
-
Trading Update Meten International Education Group
-
Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Chardan Capital Markets Starts Homology Medicines (FIXX) at Buy
-
Axovant (AXGT) Prices 14.03M Share Common Offering at $3.75/Sh
-
Axovant Gene Therapies Announces Pricing of $65 Million Public Offering
-
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
-
Newborn Acquisition Corp. (NBAC) Prices 5M Unit IPO at $10/Unit
-
Newborn Acquisition Corp. Announces Pricing of $50 Million Initial Public Offering
-
Catalyst Biosciences (CBIO) Prices 4.6M Shares at $6.50
-
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
-
UPDATE: Moderna (MRNA) Prices 26.32M Share Common Offering at $19/Sh
-
Moderna Announces Pricing of Public Offering of Shares of Common Stock
-
UPDATE: Chardan Capital Markets Upgrades Adverum Biotechnologies (ADVM) to Buy
-
Applied Genetic Technologies Corp. (AGTC) PT Raised to $10 at Chardan Capital Markets
-
Esperion Therapeutics (ESPR) PT Raised to $65 at Chardan Capital Markets
-
Buy Regenxbio (RGNX) for Breakup Story - Chardan Capital Markets
-
BioPharmX And Timber Pharmaceuticals Announce Entry into Merger Agreement
-
Chardan Capital Markets Reiterates Buy Rating on 4D Pharma Plc (DDDD:LN)
-
SPAC Research Releases League Tables Featuring Top SPAC Underwriters and Law Firms of 2019
-
Chardan Capital Markets Starts Immunovant (IMVT) at Buy; Named Top 2020 Pick
-
Exicure Announces the Closing of its Offering of Common Stock
-
Chardan Acts as M&A Advisor in Health Sciences Acquisitions Corporation Completed Merger with Immunovant
-
Exicure Inc. (XCUR) Prices 10M Share Common Offering at $2.75/Sh
-
Exicure Announces Pricing of $27.5 Million Public Offering of Common Stock

